Results 101 to 110 of about 25,189 (232)

Autologous transfusion

open access: yesBMJ, 2002
Elizabeth S, Vanderlinde   +2 more
openaire   +3 more sources

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

open access: yesHematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The optimal second‐line chemotherapy regimen for relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) remains uncertain. We retrospectively compared efficacy and safety between gemcitabine, carboplatin, dexamethasone, and rituximab (GCD‐R) and cyclophosphamide, high‐dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER ...
Yoshikazu Ikoma   +18 more
wiley   +1 more source

Feasibility and effectiveness of the novel HemoClear microfiltration cell‐salvage system in cesarean sections in South Africa

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 172, Issue 1, Page 396-405, January 2026.
Abstract Objective To test the feasibility and effectiveness of implementing the HemoClear microfiltration cell‐salvage system for cesarean sections in South Africa. Methods We conducted a prospective experimental single‐arm feasibility study collecting and processing blood from 20 adult women undergoing cesarean section in Pelonomi Tertiary Hospital ...
Nndwammbi C. Ramatsea   +5 more
wiley   +1 more source

Fresh Autologous Blood Transfusions with Extracorporeal Circulation

open access: green, 1973
John L. Ochsner   +3 more
openalex   +2 more sources

Safety Following Autologous Transplantation with Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in the Northstar Hgb-204 Study [PDF]

open access: hybrid, 2018
Mark C. Walters   +14 more
openalex   +1 more source

Melanoma: Pathogenesis and Targeted Therapy

open access: yesMedComm, Volume 7, Issue 1, January 2026.
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu   +5 more
wiley   +1 more source

Organ Transplantation: Current Status, Challenges, and Future Prospects

open access: yesMedComm, Volume 7, Issue 1, January 2026.
Organ transplantation success relies on precise modulation of the alloimmune response across distinct temporal phases of rejection. Hyperacute rejection results from preformed antibodies activating complement and causing thrombosis, while acute rejection involves T cell‐ and antibody‐mediated mechanisms that drive endothelial activation and ...
Xinqiang Li, Ruidong Ding, Jinzhen Cai
wiley   +1 more source

Home - About - Disclaimer - Privacy